Core Insights - The company reported significant revenue growth and improved profitability for fiscal year 2025, driven by the expansion of its Integrated Service Program (ISP) and operational improvements [1][4][12] Financial Highlights - Total revenue increased to $2,691,741 in 2025, a growth of approximately 26% compared to $2,131,926 in 2024 [8] - Gross profit rose to $1,810,849, with gross margin expanding to 67.3% from 63.7% in the previous year [8] - Net income improved to $457,417 in 2025, contrasting with a net loss of $259,239 in 2024 [8] - Interest expense significantly declined to $237,413 from $465,055 in 2024 due to debt restructuring [8] - The company recorded a gain of approximately $1.15 million related to the extinguishment of convertible debt, enhancing the balance sheet [8] Operational Highlights - The ISP revenue surged by 74% year-over-year to $1,121,134, indicating strong adoption among primary care providers [4] - Sales of immunotherapy treatments increased by approximately 19% year-over-year, contributing to revenue diversification [5] - The company operates a growing portfolio of healthcare solutions, including digital health decision-support tools and allergy diagnostics, which support primary care physicians in managing chronic conditions [6] Management Commentary - The President and CEO highlighted 2025 as a year of operational progress and financial strengthening, emphasizing the importance of the ISP as a long-term growth driver [7] - The company aims to expand its physician network and scale its digital health infrastructure in 2026 [7]

Core Insights - QHSLab Inc. reported strong financial results for Q1 2025, with total revenue increasing by 32.1% year-over-year to $645,419, driven by growth in Integrated Service Program (ISP) and Allergy Diagnostics [2][6][7] - The company achieved a gross profit of $429,944, up from $286,158 in the prior-year period, with gross margin expanding to 66.6% from 58.6% in Q1 2024, reflecting improved product mix and operational efficiencies [6][7] - CEO Troy Grogan emphasized the structural advantages of the company's diversified revenue model and the focus on sustainable margin expansion and shareholder value [2][6] Financial Highlights - Revenue Breakdown for Q1 2025: - Allergy Diagnostics: $264,913, up 11.7% from $237,066 in Q1 2024 - ISP Services: $162,502, up 28.0% from $127,004 in Q1 2024 - Immunotherapy: $97,329, up 12.8% from $86,325 in Q1 2024 - Clinical Study: $89,100, new revenue stream - Subscriptions: $9,285, down 49.5% from $18,370 in Q1 2024 - Shipping & Handling: $9,970, stable compared to $9,959 in Q1 2024 - Training & Other: $12,320, up 24.9% from $9,863 in Q1 2024 [2][6][7] Company Overview - QHSLab Inc. is a digital health company focused on personalized medicine through innovative population health screening and point-of-care diagnostic tools for primary care [1][4] - The company utilizes advanced artificial intelligence algorithms to enhance patient monitoring and medical care, aiming to improve healthcare outcomes while increasing revenue for physicians [4]